These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35621629)

  • 1. Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor.
    Nemeckova S; Alexova-Zurkova K; Hainz P; Krystofova J; Mackova J; Roubalova K; Stastna-Markova M; Vrana M; Vydra J
    Curr Oncol; 2022 Apr; 29(5):2928-2934. PubMed ID: 35621629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
    Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
    Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caspase-2 is essential for proliferation and self-renewal of nucleophosmin-mutated acute myeloid leukemia.
    Sakthivel D; Brown-Suedel AN; Lopez KE; Salgar S; Coutinho LE; Keane F; Huang S; Sherry KM; Charendoff CI; Dunne KP; Robichaux DJ; Vargas-Hernández A; Le B; Shin CS; Carisey AF; Poreba M; Flanagan JM; Bouchier-Hayes L
    Sci Adv; 2024 Aug; 10(31):eadj3145. PubMed ID: 39093977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML.
    Skayneh H; Jishi B; Hleihel R; Hamie M; El Hajj R; Deleuze-Masquefa C; Bonnet PA; El Sabban M; El Hajj H
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions.
    Falini B
    Am J Hematol; 2023 Sep; 98(9):1452-1464. PubMed ID: 37317978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
    Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
    Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.
    Röllig C; Bornhäuser M; Kramer M; Thiede C; Ho AD; Krämer A; Schäfer-Eckart K; Wandt H; Hänel M; Einsele H; Aulitzky WE; Schmitz N; Berdel WE; Stelljes M; Müller-Tidow C; Krug U; Platzbecker U; Wermke M; Baldus CD; Krause SW; Stölzel F; von Bonin M; Schaich M; Serve H; Schetelig J; Ehninger G
    J Clin Oncol; 2015 Feb; 33(5):403-10. PubMed ID: 25547501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecules enhancers of amyloid aggregation of C-terminal domain of Nucleophosmin 1 in acute myeloid leukemia.
    Florio D; Roviello V; La Manna S; Napolitano F; Maria Malfitano A; Marasco D
    Bioorg Chem; 2022 Oct; 127():106001. PubMed ID: 35803020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia.
    Uckelmann HJ; Haarer EL; Takeda R; Wong EM; Hatton C; Marinaccio C; Perner F; Rajput M; Antonissen NJC; Wen Y; Yang L; Brunetti L; Chen CW; Armstrong SA
    Cancer Discov; 2023 Mar; 13(3):746-765. PubMed ID: 36455613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
    Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
    Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA Class I Genotype Is Associated with Relapse Risk after Allogeneic Stem Cell Transplantation for NPM1-Mutated Acute Myeloid Leukemia.
    Narayan R; Niroula A; Wang T; Kuxhausen M; He M; Meyer E; Chen YB; Bhatt VR; Beitinjaneh A; Nishihori T; Sharma A; Brown VI; Kamoun M; Diaz MA; Abid MB; Askar M; Kanakry CG; Gragert L; Bolon YT; Marsh SGE; Gadalla SM; Paczesny S; Spellman S; Lee SJ
    Transplant Cell Ther; 2023 Jul; 29(7):452.e1-452.e11. PubMed ID: 36997024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology.
    Vascotto C; Lirussi L; Poletto M; Tiribelli M; Damiani D; Fabbro D; Damante G; Demple B; Colombo E; Tell G
    Oncogene; 2014 May; 33(22):2876-87. PubMed ID: 23831574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia.
    Shi Y; Xue Y; Wang C; Yu L
    Hematology; 2022 Dec; 27(1):609-619. PubMed ID: 35621728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia.
    Greiner J; Ono Y; Hofmann S; Schmitt A; Mehring E; Götz M; Guillaume P; Döhner K; Mytilineos J; Döhner H; Schmitt M
    Blood; 2012 Aug; 120(6):1282-9. PubMed ID: 22592607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of small molecule inhibitor NSC348884 on nucleophosmin 1-mutated acute myeloid leukemia cells.
    Zhu JF; Han LL; Ma Y; Wang YX; Zhang F
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(19):9145-9151. PubMed ID: 37843328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant NPM1 Hijacks Transcriptional Hubs to Maintain Pathogenic Gene Programs in Acute Myeloid Leukemia.
    Wang XQD; Fan D; Han Q; Liu Y; Miao H; Wang X; Li Q; Chen D; Gore H; Himadewi P; Pfeifer GP; Cierpicki T; Grembecka J; Su J; Chong S; Wan L; Zhang X
    Cancer Discov; 2023 Mar; 13(3):724-745. PubMed ID: 36455589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.
    Martelli MP; Pettirossi V; Thiede C; Bonifacio E; Mezzasoma F; Cecchini D; Pacini R; Tabarrini A; Ciurnelli R; Gionfriddo I; Manes N; Rossi R; Giunchi L; Oelschlägel U; Brunetti L; Gemei M; Delia M; Specchia G; Liso A; Di Ianni M; Di Raimondo F; Falzetti F; Del Vecchio L; Martelli MF; Falini B
    Blood; 2010 Nov; 116(19):3907-22. PubMed ID: 20634376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review.
    Liu Y; Cao Y; Lin Y; Dong WM; Lin RR; Gu Q; Xie XB; Gu WY
    Transplant Proc; 2018 Apr; 50(3):959-963. PubMed ID: 29661468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.
    van der Lee DI; Reijmers RM; Honders MW; Hagedoorn RS; de Jong RC; Kester MG; van der Steen DM; de Ru AH; Kweekel C; Bijen HM; Jedema I; Veelken H; van Veelen PA; Heemskerk MH; Falkenburg JHF; Griffioen M
    J Clin Invest; 2019 Feb; 129(2):774-785. PubMed ID: 30640174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.
    Forghieri F; Riva G; Lagreca I; Barozzi P; Bettelli F; Paolini A; Nasillo V; Lusenti B; Pioli V; Giusti D; Gilioli A; Colasante C; Galassi L; Catellani H; Donatelli F; Talami A; Maffei R; Martinelli S; Potenza L; Marasca R; Tagliafico E; Manfredini R; Trenti T; Comoli P; Luppi M
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.